SEC Form 4 · accession 0000899243-15-002579
Ultragenyx Pharmaceutical Inc. · RARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jayson Donald Alexander Dallas
Officer — See Remarks
Period of report
Aug 4, 2015
Accepted (ET)
Aug 6, 2015 · 5:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001515673
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Aug 4, 2015 | A | 10,000 | — | A | 10,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $116.45 | Aug 4, 2015 | A | 90,000 | A | — | Aug 3, 2025 | Common Stock | 90,000 | 90,000 | D |
Explanation of responses
- F1Award of Restricted Stock Units under the Company's 2014 Incentive Plan that vests with respect to 1/4th of the underlying shares on August 3, 2016 and then with respect to 1/4th of the underlying shares annually thereafter.
- F2Not applicable.
- F3The option shall vest with respect to 1/4th of the underlying shares on August 3, 2016 and then with respect to 1/48th of the underlying shares monthly thereafter.
Remarks
SVP and Chief Commercial Officer